Search

Author/Creator Gaschler-Markefski, Birgit

2. Analysis of patient-reported outcomes from the LUME-Lung 1 trial: A randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer. Issue 3 (February 2015)

Authors:
Novello, Silvia; Kaiser, Rolf; Mellemgaard, Anders; Douillard, Jean-Yves; Orlov, Sergey; Krzakowski, Maciej; von Pawel, Joachim; Gottfried, Maya; Bondarenko, Igor; Liao, Meilin; Barrueco, José; Gaschler-Markefski, Birgit; Griebsch, Ingolf; Palmer, Michael; Reck, Martin; LUME-Lung 1 Study Group
Journal:
European journal of cancer
Issue:
Volume 51:Issue 3(2015:Feb.)
Page Start:
317
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial. (December 2016)

Authors:
Hanna, Nasser H.; Kaiser, Rolf; Sullivan, Richard N.; Aren, Osvaldo Rudy; Ahn, Myung-Ju; Tiangco, Beatrice; Voccia, Isabelle; Pawel, Joachim von; Kovcin, Vladimir; Agulnik, Jason; Gaschler-Markefski, Birgit; Barrueco, José; Sikken, Patricia; Schloss, Charles; Kim, Joo-Hang
Journal:
Lung cancer
Issue:
Volume 102(2016)
Page Start:
65
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗